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Background: Hemophagocytic lymphohistiocytosis (HLH) is a relatively rare but life-threatening disease with
confusing clinical manifestations, rapidly deteriorating health, high morbidity and mortality.
Methods: To improve the recognition as well as understanding of this disorder, we analyzed clinical characteristics
and prognostic factors from 85 adult patients diagnosed with HLH in our hospital from April 2005 to June 2014.
Results: Patients with HLH displayed variable clinical markers across a wide spectrum. These included fever and
hyperferritinemia (100%), elevated lactate dehydrogenase (LDH) (98.8%), two or three cytopenia (92.2%),
splenomegaly (72.9%), hypofibrinogenemia (69.4%), hypertriglyceridemia (64.7%), hemophagocytosis (51.7%), and
hepatomegaly (24.7%). Patients with active Epstien-Barr Virus (EBV) infection had a median overall survival (OS) of
65 days. Those displaying malignancy had very poor survival (median OS: 40 days). However, patients in rheumatic
and non-EBV infection groups had relatively superior prognosis (not reached). Univariate analysis showed that
Fibrinogen (Fbg) <1.5 g/L, platelet number (PLT) <40 × 109/L and LDH ≥1000 U/L were factors that negatively
affected survival (P = 0.004, 0.000, 0.002). Multivariate analysis showed that PLT <40 × 109/L was the independent
adverse factor (HR = 0.350, 95% CI: 0.145-0.844, P = 0.019).
Conclusions: HLH had very complex clinical manifestations and high death rate. Patients with active EBV infection,
malignancy, Fbg <1.5 g/L, PLT <40 × 109/L and LDH ≥1000 U/L had high risk of death as well as inferior survival,
and these patients require systemic targeted treatments as early as possible.
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Hemophagocytic Syndrome (HPS), also known as hemo-
phagocytic lymphohistiocytosis (HLH), is a potentially
life-threatening immune system disorder characterized
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unless otherwise stated.Cytotoxic cells and macrophages cause multiorgan
damage, hemophagocytosis, and severe systemic inflam-
mation [2]. The clinical presentations of HLH were gen-
erally prolonged fever, hepatosplenomegaly, cytopenia,
hypertriglyceridemia, hyperferritinemia, and hemopha-
gocytosis in bone marrow, liver, spleen or lymph nodes
[3]. Patients with primary HLH usually have a family his-
tory of the disease, or known underlying genetic defects
which predispose them to the disease [4]. Secondary
HLH is usually caused by some etiologies including in-
fections, autoimmune diseases, malignancies, acquired
immune deficiency, as well as iatrogenic immune sup-
pression and organ or stem cell transplantation [5,6].is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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creased attention over the past ten years. More than
1500 publications on this topic have appeared since
2004. Moreover, HLH was once considered a children’s
disease (<14 years old). However, cases are being re-
ported with increasing frequency in adults [7]. Patients
with HLH present with a wide spectrum of clinical man-
ifestations, rapidly deteriorating conditions, as well as
considerable morbidity and mortality.
To improve the recognition and understanding of this
disorder in elderly HLH patients (>14 years old) in
China, we analyzed data from 85 patients diagnosed at
the First Affiliated Hospital of Nanchang University
from April 2005 to June 2014. We demonstrated the
variable clinical spectrums of these patients, and deter-




This study was approved by the institutional review board
of the First Affiliated Hospital of Nanchang University, ac-
cording to the guidelines of the 1996 Helsinki
Declaration. From April 2005 to June 2014, a total of
85 adult HLH patients were admitted to the First Affil-
iated Hospital of Nanchang University in Nanchang,
China. Review of the patient’s medical records fulfilled
the requirement for written informed consent in
regards to the study. Patients younger than 14 years
old were excluded from the study.
Retrospective evaluation included assessment of under-
lying diseases, clinical manifestations, laboratory findings,
treatments, and outcomes. Laboratory findings included
peripheral blood examination, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), albumin (ALB),
bilirubin (BIL), serum creatinine (Scr), triglycerides (TG),
lactate dehydrogenase (LDH), prothrombin time (APTT),
thrombin time (TT), fibrinogen (Fbg), serum ferritin (SF),
blood immunology, virology, bacteriology, bone marrow
morphology, flow cytometry, bone marrow tissue immu-
nohistochemical staining, imaging tests for liver, spleen,
lymph nodes including B ultrasound examination and
computerized tomography (CT). Epstein-Barr virus (EBV)
and cytomegalovirus (CMV) infection were diagnosed
based on the detection of IgM antibodies or high levels of
EBV or CMV DNA [8]. Disseminated intravascular coagu-
lation (DIC) was defined as prolonged prothrombin time,
hypofibrinogenemia, or increased fibrinogen degradation
products [9].
Diagnostic criteria of HLH
All patients were diagnosed according to revised diag-
nostic criteria guideline of the HLH-2004 protocol [3].
The diagnosis of HLH can be established if either A or Bis fulfilled: (A) genetic defect consistent with HLH in-
cluding PRF1, UNC13D, STX11, STXBP2, XIAP, AP3B1,
Rab27a, LYST or SH2D1A. (B) ≥ 5 out of 8 clinical and
laboratory criteria fulfilled: 1) fever: >38.5°C for ≥7 days,
2) splenomegaly, 3) cytopenias affecting at least two of
three lineages, 4) hypertriglyceridaemia (≥3 mmol/L) or
hypofibrinogenaemia (<1.5 g/L), 5) hyperferritinaemia
(≥500 μg/L), 6) soluble CD25 (soluble interleukin 2 re-
ceptor) >2,400 U/mL, 7) hemophagocytosis in bone mar-
row, spleen, or lymph nodes, 8) low or absent NK-cell
cytotoxicity. Only 2 out of 85 patients underwent genetic
testing but with negative results. The tests for soluble
CD25 levels and NK cell activity were not available at
our institution at the time of this study.
Treatment regimens
All 85 patients received the following treatment regimens:
1) etoposide ± glucocorticoid ± cyclosporine, 2) glucocortic-
oid ± antibiotics, 3) ECHOP (etoposide, glucocorticoid, vin-
cristine, cyclophosphamide, and adriamycin) [3,10-12].
None of the patients in this study received hematopoietic
cell transplantation after chemotherapy due to poor treat-
ment response or aggressive conditions. EBV-related HLH
patients were also treated with ganciclovir. Patients with
sepsis were administered with sensitive antibiotics. Patients
with liver lesion were given drugs protecting liver function.
Patients with anemia or coagulopathy were transfused with
red cells, fibrinogen or fresh frozen plasma.
Statistical analysis
Overall survival (OS) was calculated from the date of
treatment initiation till death. Survival curves were esti-
mated by the Kaplan–Meier method, differences be-
tween curves were tested for statistical significance using
the log-rank test. Categorical variables were compared
using nonparametric tests and the Pearson’s Chi-square
test. Multivariate analysis was performed using the cox-
regression method. A P value of < 0.05 was considered
statistically significant. All data analyses were performed
using the statistical software SPSS version 20.0.
Results
Clinical and laboratory examination characteristics in 85
patients with HLH
A total of 85 patients (64 male, 21 female) fulfilled the
HLH diagnostic criteria. The median age was 44 years
old (range, 15–72 yr). The median count of blood cells
were as follows: WBC 1.66 (0.1-14.1) × 109/L, Hb 86
(43–143) g/L, and PLT 32 (1–130) × 109/L. The clinical
manifestations and laboratory findings varied signifi-
cantly (Figure 1A). The initial symptom of 100% of the
patients was fever with temperature fluctuating from
38.5 to 41°C. The duration of fever from its onset to
diagnosis ranged from 4 to 180 days. 92.9% of patients
Figure 1 The characteristics of 85 adult HLH patients. A. The percentages of clinical symptoms, signs and laboratory examinations in 85 HLH
patients. A: fever, B: ferritin ≥500 g/L, C: LDH ≥220 U/L, D: cytopenia in two or more lineages, E: GPT >40 U/L, F: splenomegaly, G: hypofibrinogenaemia,
H: hypertriglyceridemia, I: KPTT prolonged 10 S, J: Hemophagocytosis in bone marrow, K: PT prolonged 3S, L: jaundice, M: Lymphadenopathy,
N: hepatomegaly, O: renal impairment, P: skin rash, Q: epilepsy. B. The distribution of diagnostic time in 85 HLH patients. C. The initially hospitalized
departments in 85 HLH patients.
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penia <4.0 × 109/L, or anemia <90 g/L) in 2 or more cell
lines. 25.9% of patients had two cytopenia, 67.1% had
three cytopenia, and only 7.1% of patients had sole
thrombocytopenia. 72.9% of patients had splenomegaly
protruding 1–12 cm below the left costal margin. 24.7%
patients had hepatomegaly projecting 1–5 cm below the
right costal margin. 43.5% of patients had superficial or
deep lymphadenopathy. Bone marrow smears or biopsy
revealed hemophagocytosis in 51.8% of patients. One pa-
tient had skin rash.
The most common biochemical indication was high
LDH (>220 U/L, 98.8%), followed by low hypoalbumin-
emia (<30 g/L, 89.4%), elevated levels of alanine amino-
transferase (>40 U/L, 74.1%), and elevated levels of
aspartate aminotransferase (>40 U/L, 88.2%). The median
level of ALT was 78 (14–674) U/L lower than the median
level of AST (129, range from 17–1489 U/L) (P < 0.001),
which suggested chronic hepatitis-like performance.
Hyperbilirubinemia (total bilirubin level >34 μmol/L) and
renal impairment (the level of creatinine >120 μmol/L)
accounted for 48.2% and 11.7% of patients, respectively.
58.8% and 48.2% of the patients had prolonged levels of
KPTT (10 seconds greater than control) and PT (3 secondsgreater than control). One patient presented with epilepsy
as a symptom, no other obvious neurological symptoms
were exhibited in the sample population.
In seven years from 2005.1 to 2011.12, we only diag-
nosed 20 HLH patients. With the increased understand-
ing of HLH diagnosis, 47 patients were diagnosed from
2012.1 to 2013.12. In six months from 2014.1 to 2014.6,
a total of 18 adult HLH patients were diagnosed. The
distribution of diagnostic time in 85 HLH patients is
shown in Figure 1B.
60% of patients were initially hospitalized in the de-
partment of hematology for symptoms such as fever, cy-
topenia, hypofibrinogenaemia, coagulopathy. The other
34 patients were sporadically hospitalized in various de-
partments; infections (15), gastroenterology (6), respira-
tory (6), rheumatology (4), neurology (2), or traditional
Chinese medicine department (1) (Figure 1C).
Underlying diseases in 85 patients with HLH
Table 1 presents the distribution of the underlying dis-
eases in 85 patients with HLH. The majority of under-
lying diseases in HLH patients were infectious (n = 29,
34.1%), followed by unidentified causes (n = 27, 31.8%),
malignancies (n = 23, 27.1%) and autoimmune disorders
Table 1 The distribution of underlying diseases in 85
patients with HLH

















Autoimmune disorders 6 (7.1%)
Rheumatoid arthritis 2
Systemic lupus erythematosus 2
Adult Still’s disease 2
Malignancy 23 (27.1%)
Aggressive NK cell leukemia 2
B-cell lymphoma 3
T&NK cell lymphoma 17
T lymphoblastic leukemia 1
Unknown causes 27 (31.8%)
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eases, viral infection was the most common cause, 10
(34.4%) cases were caused by EBV infection, two cases
were caused by CMV infection and one case was caused
by HIV infection. 23 patients in the population displayed
malignancy-associated HLH (M-HLH). Of these patients
two had aggressive NK cell leukemia, three had B-cell
lymphoma, seventeen had T and NK cell lymphoma, and
one patient presented a T-lymphoblastic leukemia. 11 of
the 23 patients diagnosed with M-HLH simultaneously
carried EBV infections. Specific underlying disorder(s)
were not determined in 27 of the cases due to limita-
tions in diagnostic technologies and the rapid clinical de-
terioration of the patients. Of the 27 patients, 14 proceeded
with an aggressive disease course, showing lymphadenop-
athy, splenomegaly, or cells in bone marrow leading to sus-
picion of lymphoma. However no pathological evidence of
lymphoma was found.Survival analysis
To ascertain which specific clinical or laboratory factors at
diagnosis predicted prognosis of HLH patients, we ana-
lyzed the survival data of the 85 HLH patients. Follow-up
data were obtained from 60 patients, 23 patients in the
malignancy group, 12 patients in the unknown causes
group, 20 patients in the infection group and 5 patients in
the rheumatic disease group. Follow up data was lost for 25
of the patients due to poor contact information. Analysis of
survivability in different groups is shown in Figure 2. The
causes of death were primarily organ hemorrhage and co-
agulopathy including DIC, intracranial hemorrhage, gastro-
intestinal hemorrhage, septic shock and multiple organ
dysfunction syndrome.
OS of patients in the rheumatic disease group was not
reached. The median OS of patients in the infection
group was 350 days, among the nine dead patients, five
patients had EBV infection, one patient had EBV and
CMV infection, one patient had HIV infection, and two
patients had sepsis. The OS of patients in the unexplained
cause group was 90 days. The OS of M-HLH patients was
the shortest with 40d (Figure 3A), 78.3% (18/23) of pa-
tients died within three months. We analyzed the correl-
ation of EBV infection and the prognosis of patients in
infection and malignancy groups, the result showed pa-
tients with active EBV infection had shorter survival than
patients without EBV infection in infection group (65 days
vs. not reached, P = 0.021), but no difference in malig-
nancy group.
To find some indicators to predict the risk of death in
HLH patients, we compared the difference of various la-
boratory indicators between survived and dead patients.
There was no difference among many of the indicators
including white blood cells, hemoglobin, serum ferritin,
transaminases, bilirubin and triglycerides (P > 0.05).
However, the levels of platelet count and fibrinogen in
the dead group were significantly lower than those of
the patients in the survival group (P = 0.008 and 0.045,
respectively). Also of note, lactate dehydrogenase was
higher in the dead group as compared to the survival
group (P = 0.005). The comparisons of laboratory param-
eters between patients in dead and survival groups are
shown in Table 2.
We further analyzed the potential risk factors that
might affect the prognosis of HLH. Univariate analysis
suggested that patients with Fbg <1.5 g/L (median OS,
54 ± 8.6 d vs. 140 days, P = 0.004, Figure 3B), PLT<40 ×
109/L (median OS, 44 ± 4.1 days vs. not reached, P <
0.001, Figure 3C) or LDH ≥1000 U/L (median OS, 45 ±
8.0 days vs. not reached, P = 0.002, Figure 3D) generally
had a worse outcome than the control group (Table 3).
Multivariate analysis identified PLT<40 × 109/L was only
independent predictor of poor OS (HR = 0.350, 95% CI:
0.145-0.844, P = 0.019).
Figure 2 The number of survive patients in different subgroups.
Figure 3 Survival analysis in 85 cases and different subgroups. A. Kaplan-Meier survival in 85 HLH patients. B. The survival curves of patients
in the fibrinogen (Fbg) subgroup. C. The survival curves of patients in the platelet (PLT) subgroup. D. The survival curves of patients in the lactate
dehydrogenase(LDH) subgroup.
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Table 2 The comparison of laboratory parameters between patients in death and survival groups
Group Number PLT (×109/L) Fbg (g/L) LDH (U/L)
Death group 39 27.0 (5 ~ 113) 1.02 (0.64 ~ 4.26) 1260 (234 ~ 8560)
Survival group 21 50 (18 ~ 173) 1.51 (0.68 ~ 5.78) 786 (213 ~ 1901)
P value 0.008 0.045 0.005
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HLH is an infrequent but potentially life-threatening
hyperinflammation syndrome, which is caused by a
range of inherited or secondary factors. The onset of F-
HLH is usually within the first 6 months of life, however,
patients with a later onset, even up to adulthood have
also been reported [13,14]. Five different forms of F-
HLH have so far been described and four genes (PFR1,
UNC13D, STX11, STXBP2) have been identified. Sec-
ondary HLH (sHLH) can develop at any age and is usu-
ally caused by underlying conditions such as infection,
autoimmune/rheumatologic, malignant conditions et
cetera [1]. Currently, data as reported in the literature is
not precise enough to predict the incidence of HLH, al-
though single-center studies have reported the incidence
to be 0.12/100,000 per year in familial-HLH (F-HLH) pa-
tients and 0.36/100,000 per year in M-HLH patients [15].
HLH in young children/infants, mainly occurring F-HLH
with a genetic defect, developed similar symptoms to pa-
tients from our study with a couple exceptions. Similar
symptoms included fever (91%), splenomegaly (81%), hep-
atomegaly (81%), and lymph node enlargement (43%),
however, the incidence of neurologic symptoms (47%),
and Rash (43%) might be higher in F-HLH and neurologic
symptoms occurred earlier than other symptoms accord-
ing to Zhang’s report [14]. This study has focused on the
clinical characteristics and prognostic factors of adult
HLH patients to improve the recognition and understand-
ing of this disorder.Table 3 The comparison of OS time among different
subgroup patients
Group Number* OS (d) P value
Fbg
<1.5 g/L 34 54 ± 8.6 0.004
≥1.5 g/L 25 140
LDH
<1000 U/L 22 Not reached 0.002
≥1000 U/L 34 45 ± 8.0
PLT
<40 × 109 /L 30 44 ± 4.1 0.000
≥40 × 10 9/L 25 Not reached
*Some patients lacked several results due to the retrospective property of
this study.First manifestation of HLH could resemble common
infections, malignancies, fever of unknown origin, or
autoimmune disorders [16]. The clinical features are
thought to be due to hypercytokinemia, such as tumor
necrosis factor TNF-α, interferon (IFN)-γ, interleukin
(IL)-10, IL-12, and IL-18 released by highly activated
lymphocytes and macrophages [17]. Typical clinical find-
ings are prolonged fever, insensitivity to antibiotic therapy,
and hepatosplenomegaly. Laboratory findings include cyto-
penias, usually beginning with thrombocytopenia evolving
into severe pancytopenia, hyperferritinemia, elevated trans-
aminases, hypofibrinogenemia, DIC, hypertriglyceridemia,
hypoalbuminemia, and hyponatremia [18]. Our data also
showed that patients with HLH had variable clinical spec-
trums as mentioned above (Figure 1A). Due to the confus-
ing clinical symptoms, 49% of the patients were initially
misdiagnosed and hospitalized in infectious, gastroenter-
ology, respiratory, or other departments for fever, liver le-
sion, dizziness, or gastrointestinal bleeding. Due to our
increasing recognition based on clinical and laboratory re-
port and the improvements in pathological diagnosis tech-
niques in our hospital, the numbers of patients diagnosed
as HLH raised significantly in our institution. In addition,
since deficient NK-cells activity and sCD25 are hallmark of
HLH and exhibited in major HLH patients [19], the lacking
these two tests may veil the real HLH patients numbers di-
agnosed in our institution. Therefore, we infer that the in-
cidence of HLH occur more commonly than it appeared at
least in Jiangxi state.
In this study, we queried the most common form of
HLH in adults, infection associated HLH. Infectious trig-
gers include viruses (for example, EBV, cytomegalovirus,
HIV), bacteria (for example, mycobacteria), and fungi
(for example, candida, cryptococcus) [20]. Among viral
infections, EBV is undoubtedly the major cause of HLH.
Published data have shown that very high levels of pro-
inflammatory cytokines are associated with EBV-related
HLH among Asians [21]. In our current study, 33.8% of
patients had EBV infection which is consistent with the
result of a Japanese study (33.3%) [22]. Interestingly, a
study showed a quarter of male patients with EBV-
associated HLH may have mutations in the SH2D1A
gene, which is traditionally associated with X-linked
lymphoproliferative syndrome (XLPS) immunodeficient
to EBV [23]. In our data, male HLH patients presented
with EBV infections in 36.1% of cases. In contrast,
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dence of HLH was higher in male patients than in fe-
males (3:1 ratio). Determining if the higher HLH
incidence in males was related to EBV infections will
need to be confirmed in a future study. The clinical out-
come heterogeneity of patients with EBV-HLH is strik-
ing, ranging from self-limiting to aggressive and fatal.
Some results indicated that patients with active EBV-
HLH or high EBV genome copy numbers had poor
prognosis [24,25]. In the infection subgroup, we found
patients with active EBV infection had shorter survival
than non-EBV infected patients (65d vs. not reached, P
= 0.021) but there was no significance in the M-HLH
subgroup. The high mortality rate among patients with
EBV-HLH is due to, at least in part, delays in diagnosis
that result from the similarity between its initial clinical
presentation and common infective and inflammatory
conditions. Of note, improving clinical outcomes and
diagnosing patients with refractory EBV-HLH is still chal-
lenging. However, outcomes have improved significantly
with the use of rituximab, etoposide, and HCT for these
patients [26].
We continued to investigate malignant manifestation
in HLH patients. M-HLH develops most frequently in
patients with T and NK-cell lymphoma, the strong asso-
ciation between the T-cell and NK-cell lymphomas and
HLH was reported in several previous studies [27,28]. T
and NK-cell associated HLH has also been shown to
have the lowest five year survival rate (12%) [14]. Proper
T and NK-cell function is required for clearance of anti-
genic stimuli and termination of the inflammatory re-
sponse. Aberrant T-cell and NK-cell activation results in
excessive cytokine production and sustained macrophage
activation. Clonality studies have shown that a signifi-
cant number of patients with EBV-associated HLH have
a clonal proliferation of T cells [29,30]. M-HLH can also
occur in the course of other hematological malignancies
(e.g., B-cell lymphoma, Hodgkin’s lymphoma, acute and
chronic leukemias) [31]. Ishii et al. [32] reported that in
Japan the causes of 18% of M-HLH cases were cancers
other than lymphoma such as acute myeloid leukemia
and myelodysplastic syndromes. Our results were in ac-
cordance with the above, 82.6% of the patients in this
subset (N = 23) had T and NK cell lymphoma/leukemia,
three patients had B-cell lymphoma, and one patient
had T lymphoblastic leukemia. 47.8% (11/23) of patients
simultaneously had EBV infection.
HLH patients have a high mortality rate, which is par-
tially caused by a lack of clinical suspicion and unavail-
ability of genetic as well as other molecular studies in
most developing countries. Therefore, it is necessary to
establish effective pretreatment markers to predict the
high-risk subsets in this disorder. In this study, we
further explored the prognostic factors related to HLHsurvival in clinics. Our results showed patients with M-
HLH had the worst prognosis (median OS: 40 days), and
patients in unexplained cause group also had poor out-
comes (median OS: 90 days. This may have been caused
in part by an inability to diagnose lymphoma in patients
that were suspected of having it due to lack of evidence.
To exclude the interference of different hospitalized
divisions, we compared the survival time among patients
from various departments. The results revealed that pa-
tients initially hospitalized in hematology had the short-
est survival time (median OS, 45 days), followed by
patients hospitalized in other departments (median OS,
350 days) and infectious department (median OS, not
reached) (P = 0.006) (data not shown). This result is con-
sistent with our conclusion that M-HLH and EBV infec-
tion are associated with poor survival. This is due to the
fact that there were 19 patients with lymphoma and 10 with
EBV infection admitted to the hematology department.
Also, there was no survival difference between patients di-
agnosed before and after 2011 (data not shown). Intri-
guingly, we found patients with Fbg <1.5 g/L, PLT <40 ×
109/L, or LDH ≥1000 U/L had shorter OS by using univari-
ate analysis which is consistent with our previous study in
lymphoma - associated HLH (LAHS) [33]. Furthermore,
multivariate analysis demonstrated PLT <40 × 109/L was
the sole predictor of poor OS, which is consistent with the
reports from Wang Z et al. [34,35]. The mechanism
under which PLT is operating remains elusive. We in-
ferred that PLT change might be a more direct conse-
quence of cytokine storm and hyperinflammation
compared to Fbg and LDH.
HLH is an aggressive and incurable disease. Even with
treatment and haematopoietic stem cell transplant
(HSCT), the 5-year survival probability ranges from 45%
to 75%, but the survival was 0% without HSCT treat-
ment [12]. Due to the aggressive life-threatening impli-
cations of HLH, effective treatments including therapies
that target activated macrophages/histiocytes (etopo-
side, steroids, high-dose IVIgG) and/or activated T cells
(steroids, cyclosporine A, antithymocyte globulins) [36]
should be instituted promptly, followed by HSCT. The
survival of patients diagnosed in a study conducted at
South Carolina University with EBV-HLH was signifi-
cantly improved when etoposide treatment started
within 4 weeks of diagnosis [37]. Besides, treatment on
coexisting infections, identification of other potential
triggers of HLH is also necessary. Patients who do not
respond to steroids require management with aggres-
sive combination chemotherapy, followed by HSCT. In
our group, the median OS is 60 days despite the imple-
mentation of treatments such as etoposide, glucocortic-
oid and cyclosporine. The reason for poor survival in
these patients may be as follows, the unavailability of
some high specificity indicator tests [38,39] such as
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tion resulted in delayed diagnoses and treatment of
HLH patients which led to end-organ failure and death.
Moreover, high-dose chemotherapy drugs including
etoposide and allo-HCT regimens were not applied in
these patients. These treatments could considerably
improve survival for patients with refractory EBV-
associated HLH and lymphoma [12].
In this article, our results echo clinical studies com-
pleted elsewhere that both T/NK-cell abnormalities as
well as EBV viral infection play an important role in
the disease progression [27,30,32]. This study
attempted to evaluate effective markers for diagnoses
across a wider spectrum of cases and long follow-up
time (up to 9 years). Studies in the past usually focused
on identifying sole clinical marker to this disease [37].
With a better idea of confidence and significance, we dis-
close the importance of factors like malignance disease
and EBV infection et al. simultaneously on the sHLH
based on a comprehensive interpretation of solid sample.
However, other studies showed some different prognostic
factors such as the high level of serum ferritin to our data
[35]. More studies would need to be performed to verify
these results.
Conclusions
Taken together, our data revealed HLH adult patients had
a variable clinical spectrum as well as underlying diseases.
Patients with active EBV infection and lymphoma had
poor survival. Patients with Fbg <1.5 g/L, PLT <40 × 109/L
and LDH ≥1000 U/L had high risk of death as well as in-
ferior survival, and effective treatment like high-dosage
chemotherapy combined with HSCT might be critical to
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